达拉图穆马
医学
内科学
耐火材料(行星科学)
多发性骨髓瘤
肿瘤科
临床试验
外科
硼替佐米
天体生物学
物理
作者
Saad Z. Usmani,Brendan M. Weiss,Torben Plesner,Nizar J. Bahlis,Andrew Belch,Sagar Lonial,Henk M. Lokhorst,Peter M. Voorhees,Paul G. Richardson,Ajai Chari,A. Kate Sasser,Amy Axel,Huaibao Feng,Clarissa Uhlar,Jianping Wang,Imran Khan,Tahamtan Ahmadi,Hareth Nahi
出处
期刊:Blood
[American Society of Hematology]
日期:2016-07-07
卷期号:128 (1): 37-44
被引量:355
标识
DOI:10.1182/blood-2016-03-705210
摘要
Key Points A pooled analysis of 2 daratumumab trials showed no new safety signals, an overall response rate of 31%, and deep and durable responses. Median overall survival was 20.1 months; benefit was also shown in patients who achieved minimal response/stable disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI